黑料吃瓜群网

Is there an optimal blood pressure drug for every person?


Thursday, 13 April, 2023

Is there an optimal blood pressure drug for every person?

The number of people with hypertension has doubled, and around a third of adults aged 30鈥79 have the condition聽鈥 1.28 billion people worldwide. Untreated hypertension can lead to kidney disease, heart disease and stroke, accounting for 11.3 million deaths in 2021 alone.

Only a small minority of patients get their blood pressure under control with drug therapy. A part of the problem may be that the efficacy of treatments differs between individuals. A key question is whether tailoring drug choice to the individuals can make a difference.

To address this question, the Precision Hypertension Care Study (PHYSIC) sequentially tested four different blood pressure lowering medicines in 280 people with hypertension in Sweden. The study showed that the benefit for individuals varied according to the medication given.

For many people, matching the right treatment to the right individual was better than doubling the dose of a non-tailored drug and almost as good as adding a second drug.

Principal investigator Johan Sundstr枚m, Professor of Epidemiology at Uppsala University and Conjoint Professor at , said, 鈥淲ith these findings, we have evidence that existing blood pressure treatments can be optimised for maximum patient benefit. Personalised treatment may reduce the need for higher doses and multiple medications, with the potential to improve treatment adherence, patient outcomes and cost efficacy.鈥

The PHYSIC trial sets the groundwork for further research into personalised medicine to treat hypertension. Professor Bruce Neal, Executive Director for The George Institute, Australia and a co-author on the research, said, 鈥淧ersonally tailored treatment is now the standard of care for many patients with cancer, but personalised medicine has been much slower to take off in the cardiovascular field. This research shows that there is real potential for tailoring something as simple as blood pressure lowering treatment.鈥

However, he added, 鈥淭he next challenge we need to overcome is how to do this at scale. Although we showed the potential in this research study, we don鈥檛 yet have the tools to do it in practice.鈥 The results were published in the Journal of the American Medical Association (JAMA).

Image credit: iStockphoto.com/Casanowe

Related News

Victoria's Q3 median ED wait times the lowest on record

Victoria's quarter three performance data (January–March) has shown improvement across...

Irregularities in a clinician's cases prompt 15-month lookback

St Vincent's 黑料吃瓜群网 Sydney has detailed a 15-month lookback review — prompted by...

Two researchers receive $899,000 in cardiovascular funding

In heart-related news this Heart Week (5–11 May), two University of Newcastle researchers...



Content from other channels on our network


  • All content Copyright 漏 2025 黑料吃瓜群网-Farrow Pty Ltd